Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Gastric Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 50 articles: HTML format

Single Articles

April 2021
1. DEGIULI M, Reddavid R, Tomatis M, Ponti A, et al
   D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.
   Eur J Cancer. 2021;150:10-22.
   PubMed     Abstract available
   
   
   December 2020
2. PARK S, Nam CM, Kim SG, Mun JE, et al
   Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
   Eur J Cancer. 2020;144:49-60.
   PubMed     Abstract available
   
   
   November 2020
3. DIJKSTERHUIS WPM, Verhoeven RHA, Pape M, Slingerland M, et al
   Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
   Eur J Cancer. 2020;139:107-118.
   PubMed     Abstract available
   
   
   September 2020
4. ATHAUDA A, Nankivell M, Langley RE, Alderson D, et al
   Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
   Eur J Cancer. 2020;137:45-56.
   PubMed     Abstract available
   
   
   August 2020
5. GIULIANI J, Bonetti A
   Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
   Eur J Cancer. 2020;138:77-79.
   PubMed    
   
   
   
6. BANG YJ, Golan T, Dahan L, Fu S, et al
   Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
   Eur J Cancer. 2020;137:272-284.
   PubMed     Abstract available
   
   
   May 2020
7. NISHIKAWA K, Murotani K, Fujitani K, Inagaki H, et al
   Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TR
   Eur J Cancer. 2020;132:159-167.
   PubMed     Abstract available
   
   
   
8. VAN DER KAAIJ RT, Koemans WJ, van Putten M, Snaebjornsson P, et al
   A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
   Eur J Cancer. 2020;130:23-31.
   PubMed     Abstract available
   
   
   
9. ZHENG Y, Yang X, Yan C, Feng R, et al
   Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
   Eur J Cancer. 2020;130:12-19.
   PubMed     Abstract available
   
   
   April 2020
10. KAWAZOE A, Yamaguchi K, Yasui H, Negoro Y, et al
    Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Eur J Cancer. 2020;129:97-106.
    PubMed     Abstract available
    
    
    March 2020
11. SLAGTER AE, Tudela B, van Amelsfoort RM, Sikorska K, et al
    Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial.
    Eur J Cancer. 2020;130:146-154.
    PubMed     Abstract available
    
    
    February 2020
12. LIU X, Cao Y, Li R, Gu Y, et al
    Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
    Eur J Cancer. 2020;128:27-37.
    PubMed     Abstract available
    
    
    January 2020
13. VAN CUTSEM E, Muro K, Cunningham D, Bodoky G, et al
    Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Eur J Cancer. 2020;127:150-157.
    PubMed     Abstract available
    
    
    
14. WAGNER AD, Lordick F, Grabsch HI, Terashima M, et al
    Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
    Eur J Cancer. 2020;124:67-76.
    PubMed     Abstract available
    
    
    November 2019
15. THOMAS A, Virdee PS, Eatock M, Lord SR, et al
    Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
    Eur J Cancer. 2019;124:131-141.
    PubMed     Abstract available
    
    
    June 2019
16. OBERMANNOVA R, Valik D, Hasenclever D, Zdrazilova-Dubska L, et al
    High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.
    Eur J Cancer. 2019;116:107-113.
    PubMed     Abstract available
    
    
    March 2019
17. KIM C, Chon HJ, Kim JH, Jung M, et al
    Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
    Eur J Cancer. 2019;112:20-28.
    PubMed     Abstract available
    
    
    December 2018
18. CHAU I, Fuchs CS, Ohtsu A, Barzi A, et al
    Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
    Eur J Cancer. 2018;107:115-123.
    PubMed     Abstract available
    
    
    November 2018
19. SAEKI H, Oki E, Kashiwada T, Arigami T, et al
    Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Eur J Cancer. 2018;105:41-49.
    PubMed     Abstract available
    
    
    September 2018
20. SAHIN U, Schuler M, Richly H, Bauer S, et al
    A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
    Eur J Cancer. 2018;100:17-26.
    PubMed     Abstract available
    
    
    August 2018
21. NISHIKAWA K, Tsuburaya A, Yoshikawa T, Kobayashi M, et al
    A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Eur J Cancer. 2018;101:220-228.
    PubMed     Abstract available
    
    
    July 2018
22. MIZRAK KAYA D, Nogueras-Gonzales GM, Harada K, Amlashi FG, et al
    Potentially curable gastric adenocarcinoma treated without surgery.
    Eur J Cancer. 2018;98:23-29.
    PubMed     Abstract available
    
    
    April 2018
23. STAHL M, Maderer A, Lordick F, Mihaljevic AL, et al
    Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (
    Eur J Cancer. 2018;93:119-126.
    PubMed     Abstract available
    
    
    March 2018
24. HEWITT LC, Inam IZ, Saito Y, Yoshikawa T, et al
    Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Eur J Cancer. 2018;94:104-114.
    PubMed     Abstract available
    
    
    
25. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    Potential impact of molecular classification on tailored lymphadenectomy for gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S8.
    PubMed    
    
    
    
26. CHIAPPA A, Bertani E, Fazio N, Foschi D, et al
    D2-lymphadenectomy and gastric resection in a consecutive series of patients with gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S7.
    PubMed    
    
    
    
27. BENCIVENGA M, Treppiedi E, Verlato G, Mengardo V, et al
    The amount of cells with Signet Ring Cell morphology has a prognostic impact in poorly cohesive gastric carcinoma.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    PubMed    
    
    
    
28. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    K-RAS mutation in gastric cancer and its link with microsatellite instability status.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    PubMed    
    
    
    
29. CARNEIRO F
    Hereditary gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4.
    PubMed    
    
    
    
30. ROVIELLO F
    The role of HIPEC in gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4-S5.
    PubMed    
    
    
    
31. TERASHIMA M
    Perioperative treatment strategies and current studies to improve gastric cancer outcomes in Japan.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed    
    
    
    
32. LORDICK F
    Response-adapted treatment stratification in oesophago-gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed    
    
    
    
33. LAURENT-PUIG P
    Oesophago-gastric cancer: One disease or separate entities?: Translating molecular subtyping into clinical practice.
    Eur J Cancer. 2018;92 Suppl 2:S1.
    PubMed    
    
    
    
34. NASR F, El Rassy E, Maalouf G, Azar C, et al
    Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
    Eur J Cancer. 2018;91:171-173.
    PubMed    
    
    
    February 2018
35. SPOERL S, Novotny A, Al-Batran SE, Lordick F, et al
    Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
    Eur J Cancer. 2018;90:26-33.
    PubMed     Abstract available
    
    
    January 2018
36. BANDO H, Shimodaira H, Fujitani K, Takashima A, et al
    A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Eur J Cancer. 2018;91:86-91.
    PubMed     Abstract available
    
    
    December 2017
37. WANG H, Li B, Liu Z, Gong J, et al
    HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Eur J Cancer. 2017;88:92-100.
    PubMed     Abstract available
    
    
    August 2017
38. COURTOIS S, Duran RV, Giraud J, Sifre E, et al
    Metformin targets gastric cancer stem cells.
    Eur J Cancer. 2017;84:193-201.
    PubMed     Abstract available
    
    
    
39. STAHL M, Walz MK, Riera-Knorrenschild J, Stuschke M, et al
    Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
    Eur J Cancer. 2017;81:183-190.
    PubMed     Abstract available
    
    
    
40. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed    
    
    
    July 2017
41. PARK SR, Kim MJ, Nam BH, Kim CG, et al
    A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
    Eur J Cancer. 2017;83:32-42.
    PubMed     Abstract available
    
    
    
42. KEMPF E, Tournigand C, Rochigneux P, Aubry R, et al
    Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
    Eur J Cancer. 2017;79:31-40.
    PubMed     Abstract available
    
    
    
43. PERNOT S, Badoual C, Terme M, Castan F, et al
    Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
    Eur J Cancer. 2017;79:15-22.
    PubMed     Abstract available
    
    
    June 2017
44. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    PubMed     Abstract available
    
    
    
45. HAJ MOHAMMAD N, Bernards N, van Putten M, Lemmens VEPP, et al
    Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
    Eur J Cancer. 2017;78:28-36.
    PubMed     Abstract available
    
    
    May 2017
46. FARAG S, Somaiah N, Choi H, Heeres B, et al
    Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Eur J Cancer. 2017;76:76-83.
    PubMed     Abstract available
    
    
    
47. PETRELLI F, Tomasello G, Barni S
    Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Eur J Cancer. 2017;76:8-16.
    PubMed     Abstract available
    
    
    April 2017
48. DESIDERIO J, Chao J, Melstrom L, Warner S, et al
    The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
    Eur J Cancer. 2017;79:1-14.
    PubMed     Abstract available
    
    
    February 2017
49. IENI A, Angelico G, Zeppa P, Tuccari G, et al
    Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER
    Eur J Cancer. 2017;75:190-191.
    PubMed    
    
    
    December 2016
50. OH HJ, Lim CH, Yoon BH, Yoon SB, et al
    Fracture after gastrectomy for gastric cancer: A long-term follow-up observational study.
    Eur J Cancer. 2016;72:28-36.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: